Juno Therapeutics (JUNO) Cut to Hold at Raymond James Financial

Screen Shot 2018 01 22

Markets Insider

About 35.80 million shares traded or 1164.79% up from the average. Juno Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Klausner Richard has sold 12,724 shares of Juno Therapeutics, Inc. It has underperformed by 16.70% the S&P500. It also increased its holding in Intra (NASDAQ:ITCI) by 50,000 shares in the quarter, for a total of 2.20M shares, and has risen its stake in Esperion Therapeutics Inc.

Juno Therapeutics (NASDAQ:JUNO) last announced its earnings results on Wednesday, November 1st. The high and low revenue estimates for the current quarter are $24.3 Million and $8 Million, respectively. The company's revenue for the quarter was up 115.4% compared to the same quarter previous year.

Among 19 analysts covering Juno Therapeutics Inc (NASDAQ:JUNO), 8 have Buy rating, 1 Sell and 10 Hold. Therefore 44% are positive.

The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 2.10 for JUNO and 2.20 for ONCE, which implies that analysts are more bullish on the outlook for ONCE. The Motley Fool recommends Editas Medicine and Juno Therapeutics. SunTrust has "Buy" rating and $65.0 target. The stock is a Buy among 2 brokerage firms polled by Factset Research. (NASDAQ:JUNO) has "Buy" rating given on Friday, November 3 by Raymond James. The firm has "Reduce" rating by Standpoint Research given on Thursday, August 31.

"What you're seeing is the belief that they will ultimately, whether it's today or in the next few days, come to some kind of a bipartisan agreement on the budget, and the market is reflecting its confidence", said Ryan Larson, head of USA equity trading at RBC Global Asset Management in Chicago.

S.Africa's ANC confirms talks on Zuma exit
However, several South African media outlets say some senior ruling party officials are working to replace Zuma with Ramaphosa as president.

Juno has contributed to the development of chimeric antigen receptor, or "CAR" therapy, and T-cell receptor therapeutics. "The company has negative record of earnings surprises in recent quarters". High Durable CR Rates in Relapsed/Refractory (R/R) Aggressive B-NHL Treated with the CD19-Directed CAR T Cell Product JCAR017 (TRANSCEND NHL 001): Defined Composition Allows for Dose-Finding and Definition of Pivotal Cohort.

Investors sentiment increased to 1.44 in 2017 Q3. 0 analysts call it Underweight, while 1 think it is Overweight. Wells Fargo & Co cut shares of Juno Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday, December 12th. In terms of relative volume, these shares are trading at 1.89x their normal volume. The California-based California State Teachers Retirement System has invested 0.01% in Juno Therapeutics, Inc. (NASDAQ:JUNO) for 46,435 shares. The stock climbed 61.5 percent over the past quarter, while surged 150.72 percent over the past six months. Hudson Bay Capital LP has 70,000 shares for 0.08% of their portfolio. Next reported 0% stake. Partner Fund Mgmt Limited Partnership stated it has 1.45 million shares.

A number of hedge funds have recently bought and sold shares of JUNO.

Once feted for its year-on-year growth, Celgene's stock crashed 30% last October after it pared back its future growth forecasts. These shares are worth $613,424 and were traded at $48.21 each. It is down 0.00% since January 22, 2017 and is. It has outperformed by 12.60% the S&P500. (NASDAQ:LAKE) to report earnings on April, 25. Alpine Glob Management Ltd Com holds 0.06% or 5,000 shares. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. "They've got to be seen to be doing things, otherwise they really struggle to convince investors".

Latest News